Sushilkumar K Sonavane1, Paul Pinsky2, Jubal Watts3, David S Gierada4, Reginald Munden5, Satinder P Singh3, Hrudaya Nath3. 1. Department of Radiology- Cardiopulmonary section, University of Alabama in Birmingham School of Medicine, 619 19th St S JTN 363, Birmingham, AL, 35233, USA. ssonavane@uabmc.edu. 2. Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA. 3. Department of Radiology- Cardiopulmonary section, University of Alabama in Birmingham School of Medicine, 619 19th St S JTN 363, Birmingham, AL, 35233, USA. 4. Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA. 5. Department of Radiology, Wake Forest School of Medicine, Winston Salem, NC, USA.
Abstract
PURPOSE: The National Lung Screening Trial (NLST) demonstrated a reduction in lung cancer and all-cause mortality with low-dose CT (LDCT) screening. The aim of our study was to examine the time to diagnosis (TTD) of lung cancer in the LDCT arm of the NLST and assess its relationship with cancer characteristics and survival. METHODS: The subjects (N = 462) with a positive baseline screen and subsequent lung cancer diagnosis within 3 years were evaluated by data and image review to confirm the baseline abnormality. The cases were analysed for the relationship between TTD and imaging features, cancer type, stage and survival for 7 years from baseline screen. RESULTS: Cancer was judged to be present at baseline in 397/462 cases. The factors that showed significant association (p value trend less than 0.05) with longer TTD included smaller nodule size, pure ground glass nodules (GGNs), smooth/lobulated margins, stages I/II, adenocarcinoma, and decreasing lung cancer mortality. The logistic regression model for lung cancer death showed significant inverse relationships with size less than 20 mm (OR = 0.32), pure GGNs (OR = 0.24), adenocarcinoma (OR = 0.57) and direct relationship with age (OR = 1.4). CONCLUSION: TTD after a positive LDCT screen in the NLST showed a strong association with imaging features, stage and mortality. KEY POINTS: • NLST observed variable time to lung cancer diagnosis from positive baseline screen. • Time to diagnosis was associated with imaging features, cancer type and stage. • In univariate but not multivariate analysis, longer TTD correlated with decreased mortality.
PURPOSE: The National Lung Screening Trial (NLST) demonstrated a reduction in lung cancer and all-cause mortality with low-dose CT (LDCT) screening. The aim of our study was to examine the time to diagnosis (TTD) of lung cancer in the LDCT arm of the NLST and assess its relationship with cancer characteristics and survival. METHODS: The subjects (N = 462) with a positive baseline screen and subsequent lung cancer diagnosis within 3 years were evaluated by data and image review to confirm the baseline abnormality. The cases were analysed for the relationship between TTD and imaging features, cancer type, stage and survival for 7 years from baseline screen. RESULTS:Cancer was judged to be present at baseline in 397/462 cases. The factors that showed significant association (p value trend less than 0.05) with longer TTD included smaller nodule size, pure ground glass nodules (GGNs), smooth/lobulated margins, stages I/II, adenocarcinoma, and decreasing lung cancer mortality. The logistic regression model for lung cancer death showed significant inverse relationships with size less than 20 mm (OR = 0.32), pure GGNs (OR = 0.24), adenocarcinoma (OR = 0.57) and direct relationship with age (OR = 1.4). CONCLUSION: TTD after a positive LDCT screen in the NLST showed a strong association with imaging features, stage and mortality. KEY POINTS: • NLST observed variable time to lung cancer diagnosis from positive baseline screen. • Time to diagnosis was associated with imaging features, cancer type and stage. • In univariate but not multivariate analysis, longer TTD correlated with decreased mortality.
Authors: Denise R Aberle; Sarah DeMello; Christine D Berg; William C Black; Brenda Brewer; Timothy R Church; Kathy L Clingan; Fenghai Duan; Richard M Fagerstrom; Ilana F Gareen; Constantine A Gatsonis; David S Gierada; Amanda Jain; Gordon C Jones; Irene Mahon; Pamela M Marcus; Joshua M Rathmell; JoRean Sicks Journal: N Engl J Med Date: 2013-09-05 Impact factor: 91.245
Authors: Hilary A Robbins; Hormuzd A Katki; Li C Cheung; Rebecca Landy; Christine D Berg Journal: J Thorac Oncol Date: 2019-05-22 Impact factor: 15.609
Authors: Helen Hall; Adam Tocock; Sarah Burdett; David Fisher; William M Ricketts; John Robson; Thomas Round; Sarita Gorolay; Emma MacArthur; Donna Chung; Sam M Janes; Michael D Peake; Neal Navani Journal: Thorax Date: 2021-08-17 Impact factor: 9.102
Authors: Chyke A Doubeni; Nicole B Gabler; Cosette M Wheeler; Anne Marie McCarthy; Philip E Castle; Ethan A Halm; Mitchell D Schnall; Celette S Skinner; Anna N A Tosteson; Donald L Weaver; Anil Vachani; Shivan J Mehta; Katharine A Rendle; Stacey A Fedewa; Douglas A Corley; Katrina Armstrong Journal: CA Cancer J Clin Date: 2018-03-30 Impact factor: 508.702